Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial
Letter
[키워드] 1:1
absence
Admission
allergy
alteration
Antibody test
anticipated
Antigen
approved
assigned
blinded
breast-feeding
Burgos
Cancer
chronic liver disease
cirrhosis
clearance
clinical
clinical symptom
clinical trial
Complete
Corticosteroid
Course
COVID-19
COVID19
creatinine
criteria
delirium
Department
Desaturation
Deterioration
diabete
Diagnosis
dissemination
drug
Dyspnea
Early pulmonary
early stage
Effectiveness
element
Emergency
EudraCT
evaluate
exclusion
for inclusion
glucocorticoid
greater
group
heart
hidden
history
HIV infection
hospital
Hospital admission
Hospital stay
Hydroxychloroquine
hypertension
ICU admission
Immunosuppression
immunosuppressive
include
Inclusion
intention-to-treat basis
interactions
Intervention
local Ethics Committee
lung
lung involvement
meet
mild pneumonia
modify
number
objective
observation
Occurrence
Other
other diseases
outcome
Outpatient
outpatients
Paracetamol
parallel group
participant
Participation
Patient
patients’ medical records
PCR
per protocol
performed
physician
Pneumonia
power of 80%
Prednisone
professionals
protocol
pulmonary involvement
QT prolongation
radiological
random
randomised
randomised controlled trial
Randomized
receive
recruitment
reduce
reflected
Registered
renal
responsible
risk
Sample size
SARS-COV-2 infection
sealed
secondary
sequence
Spain
Spanish
status
steroid
Steroids
stratified
Stratified randomization
study drug
study inclusion
subject
Symptom
the patient
Treatment
Trial
verbal
website
women
X-ray
[DOI] 10.1186/s13063-020-04575-w PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04575-w PMC 바로가기 [Article Type] Letter